Biohaven Quarterly Income Statement
NYSE: BHVNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
12.08+0.15 (+1.26%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Pre-market: 12.30 +1.82%
Biohaven revenue and earnings
Biohaven reported a net loss of $137.3 million, compared with a loss of $198.1 million a year earlier. Diluted earnings per share came in at -$0.91.
Summary generated from market data by MetaCap's automated system. Methodology
Biohaven income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research & Development | 100.81M | 103.83M | 121.94M | 141.17M | 184.37M | 187.58M | 167.47M | 157.61M | 314.82M | 155.97M | 134.81M | 95.52M |
| Operating Income | -124.90M | -130.43M | -142.73M | -169.38M | -211.70M | -221.56M | -189.93M | -178.17M | -333.77M | -183.24M | -153.71M | -110.55M |
| Other Income (Expense) | -12.02M | 168.00K | -2.47M | -3.84M | 13.81M | 493.00K | 3.14M | 17.80M | 14.18M | 4.30M | 7.74M | 4.69M |
| Pretax Income | -136.92M | -130.26M | -145.20M | -173.22M | -197.89M | -221.07M | -186.79M | -160.36M | -319.59M | -178.94M | -145.97M | -105.86M |
| Income Tax | 391.00K | 272.00K | 351.00K | 221.00K | 261.00K | 609.00K | 48.00K | -59.00K | 177.00K | 569.00K | -1.21M | -3.29M |
| Net Income | -137.31M | -130.53M | -145.56M | -173.44M | -198.15M | -221.68M | -186.84M | -160.30M | -319.77M | -179.50M | -144.76M | -102.57M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -0.91 | -0.88 | -1.11 | -1.64 | -1.94 | -2.17 | -1.74 | -1.70 | -3.64 | -2.20 | -1.88 | -1.50 |
| EPS (Diluted) | -0.91 | -0.88 | -1.11 | -1.64 | -1.94 | -2.17 | -1.74 | -1.70 | -3.64 | -2.20 | -1.88 | -1.50 |
| Shares Outstanding (Basic) | 150.64M | 147.62M | — | 105.82M | 102.37M | 101.94M | — | 94.37M | 87.77M | 81.60M | — | 68.32M |
| Shares Outstanding (Diluted) | 150.64M | 147.62M | — | 105.82M | 102.37M | 101.94M | — | 94.37M | 87.77M | 81.60M | — | 68.32M |
| EBITDA | -122.64M | -128.06M | -140.16M | -166.26M | -209.72M | -219.31M | -187.47M | -176.17M | -331.82M | -181.79M | -151.82M | -109.01M |
This table shows 12 quarterly periods of Biohaven's income statement, from Q2 2026 back to Q3 2023, across 11 line items including research & development, operating income, other income (expense). Values in USD; B = billions, M = millions. Fiscal periods follow BHVN's reporting calendar. What is a income statement?